Pasar al contenido principal

VALIDACION DE LA PROTEINA SALIVAL LACTOFERRINA COMO BIOMARCADOR DE LA ENFERMEDAD DE ALZHEIMER: ALTERNATIVA AL DIAGNOSTICO Y MECANISMO PATOGENICO

PI18/00118

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL 12 DE OCTUBRE
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL 12 DE OCTUBRE (i+12)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer’s disease experimental models

  • de la Cueva, Macarena
  • Antequera, Desiree
  • Ordoñez-Gutierrez, Lara
  • Wandosell, Francisco
  • Camins, Antonio
  • Carro, Eva
  • Bartolomé, Fernando
The most accepted hypothesis in Alzheimer’s disease (AD) is the amyloid cascade which establishes that Aβ accumulation may induce the disease development. This accumulation may occur years before the clinical symptoms but it has not been elucidated if this accumulation is the cause or the consequence of AD. It is however, clear that Aβ accumulation exerts toxic effects in the cerebral cells. It is important then to investigate all possible associated events that may help to design new therapeutic strategies to defeat or ameliorate the symptoms in AD. Alterations in the mitochondrial physiology have been found in AD but it is not still clear if they could be an early event in the disease progression associated to amyloidosis or other conditions. Using APP/PS1 mice, our results support published evidence and show imbalances in the mitochondrial dynamics in the cerebral cortex and hippocampus of these mice representing very early events in the disease progression. We demonstrate in cellular models that these imbalances are consequence of Aβ accumulation that ultimately induce increased mitophagy, a mechanism which selectively removes damaged mitochondria by autophagy. Along with increased mitophagy, we also found that Aβ independently increases autophagy in APP/PS1 mice. Therefore, mitochondrial dysfunction could be an early feature in AD, associated with amyloid overload., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects “PI18/00118”, “PI21/00183” and “CP20/00007” and co-funded by the European Union, Comunidad de Madrid (S2017/BMD-3700; NEUROMETAB-CM), and CIBERNED (CB07/502). In addition FW was supported by grants from ISCIII-CIBERNED (CB06/05/0067) and I+D+i-RETOS- RTI2018-096303-B.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus, implication for Alzheimer's disease

  • Bartolome, Fernando|||0000-0001-9322-8933
  • Krzyzanowska, Agnieszka
  • de la Cueva, Macarena
  • Pascual, Consuelo
  • Antequera, Desiree
  • Spuch, Carlos
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Rábano, Alberto|||0000-0001-9320-6566
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Hardy, John|||0000-0002-3122-0423
  • Abramov, Andrey Y.
  • Carro, Eva|||0000-0002-6504-4579
In Alzheimer's disease (AD) amyloid-β (Aβ) deposits may cause impairments in choroid plexus, a specialised brain structure which forms the blood-cerebrospinal fluid (CSF) barrier. We previously carried out a mass proteomic-based study in choroid plexus from AD patients and we found several differentially regulated proteins compared with healthy subjects. One of these proteins, annexin A5, was previously demonstrated implicated in blocking Aβ-induced cytotoxicity in neuronal cell cultures. Here, we investigated the effects of annexin A5 on Aβ toxicity in choroid plexus. We used choroid plexus tissue samples and CSF from mild cognitive impairment (MCI) and AD patients to analyse Aβ accumulation, cell death and annexin A5 levels compared with control subjects. Choroid plexus cell cultures from rats were used to analyse annexin A5 effects on Aβ-induced cytotoxicity. AD choroid plexus exhibited progressive reduction of annexin A5 levels along with progressive increased Aβ accumulation and cell death as disease stage was higher. On the other hand, annexin A5 levels in CSF from patients were found progressively increased as the disease stage increased in severity. In choroid plexus primary cultures, Aβ administration reduced endogenous annexin A5 levels in a time-course dependent manner and simultaneously increased annexin A5 levels in extracellular medium. Annexin A5 addition to choroid plexus cell cultures restored the Aβ-induced impairments on autophagy flux and apoptosis in a calcium-dependent manner. We propose that annexin A5 would exert a protective role in choroid plexus and this protection is lost as Aβ accumulates with the disease progression. Then, brain protection against further toxic insults would be jeopardised.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

  • González-Sánchez, Marta|||0000-0001-9155-1438
  • Jiménez, Javier
  • Narváez García, Arantzazu|||0000-0001-8141-558X
  • Antequera, Desiree
  • Llamas-Velasco, Sara|||0000-0002-9174-2610
  • Herrero San-Martín, Alejandro
  • Molina Arjona, Jose Antonio
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Lleó, Alberto|||0000-0002-2568-5478
  • Marco, María Pilar|||0000-0002-4064-1668
  • Rodríguez-Núñez, Montserrat
  • Pérez-Martínez, David Andrés|||0000-0001-5587-0415
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Bartolome, Fernando|||0000-0001-9322-8933
  • Domínguez, Elena
  • Carro, Eva M.
Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.